Thu, Feb 26, 2015, 7:09 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

InterMune, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • jacosa jacosa Dec 21, 2010 11:20 AM Flag

    Low efficacy and causes cancer?

    Do your homework, and you'll see that even if it DID cause cancer (it probably doesn't) it's a must-use drug.

    What's on offer here is 1 extra year of 'decent' health to people looking at a 5-year life expectancy (and a terminal phase that isn't too hard on the patient, but really tears up the family)

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Any man who would leave his family in hock to their eyeballs just to gain such a small modicum of personal comfort for a very short time on his death bed doesn't deserve to live another minute. If it were me I'd put a gun to my head and be done with it.

      • 1 Reply to tontorabinowitz
      • Don't let me stop you. Do it now.

        With ordinarily good care, the heart increases its workload as the lungs become less effective. Quality of life and family interactions remain pretty decent. Eventually, either the heart enlarges so much that it competes for chest volume with the lungs, or the left ventriclar wall becomes so thick that it can no longer contract into the right shape to pump effectively. Then stuff goes bad.

    • <What's on offer here is 1 extra year of 'decent' health to people looking at a 5-year life expectancy (and a terminal phase that isn't too hard on the patient, but really tears up the family)>

      it DOES NOT offer DECENT health at all...you will stay in the same state of BAD health even if this drug don't KILL you from CANCER!!!

 
ITMN
73.890.00(0.00%)Sep 26 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.